LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Splenic Marginal Zone B-Cell Lymphoma With Splenic Infarction in a Patient With Cold Agglutinin Disease.

Nakamoto, Ryusuke / Okuyama, Chio / Utsumi, Takahiko / Yamamoto, Yoshihiro

2019 Volume 44, Issue 5, Page(s) e372–e374

Abstract: We report a case of splenic marginal zone B-cell lymphoma discovered in a 73-year-old man with cold agglutinin disease. PET/CT revealed splenomegaly with focally intense uptake of F-FDG and diffusely increased bone marrow uptake, which was considered to ... ...

Abstract	We report a case of splenic marginal zone B-cell lymphoma discovered in a 73-year-old man with cold agglutinin disease. PET/CT revealed splenomegaly with focally intense uptake of F-FDG and diffusely increased bone marrow uptake, which was considered to be secondary to hemolytic anemia. Splenectomy was performed. The histopathology of the spleen showed splenic marginal zone B-cell lymphoma with partial splenic infarction, which correlated with the area of focal intense FDG uptake. Depending on the time since onset, splenic infarctions can present as focal FDG accumulation.
MeSH term(s)	Aged ; Anemia, Hemolytic, Autoimmune/complications ; Anemia, Hemolytic, Autoimmune/diagnostic imaging ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma, B-Cell, Marginal Zone/complications ; Lymphoma, B-Cell, Marginal Zone/diagnostic imaging ; Male ; Positron Emission Tomography Computed Tomography ; Radiopharmaceuticals ; Splenic Infarction/diagnostic imaging ; Splenic Neoplasms/complications ; Splenic Neoplasms/diagnostic imaging
Chemical Substances	Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
Language	English
Publishing date	2019-03-19
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	197628-x
ISSN	1536-0229 ; 0363-9762
ISSN (online)	1536-0229
ISSN	0363-9762
DOI	10.1097/RLU.0000000000002528
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1276: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis].

Nakao, Kensuke / Oka, Satoshi / Utsumi, Takahiko / Yamada, Seiko / Kondo, Toshinori / Tohyama, Kaoru / Asagoe, Kohsuke

Rinsho ketsueki] The Japanese journal of clinical hematology

2019 Volume 60, Issue 8, Page(s) 915–919

Abstract: A 83-year-old female patient was admitted to our hospital due to hematological manifestation of juvenile granulocytes and macrocytic anemia. Bone marrow (BM) examination revealed erythroid dysplasia and cytoplasmic blasts, and hence the patient was ... ...

Abstract	A 83-year-old female patient was admitted to our hospital due to hematological manifestation of juvenile granulocytes and macrocytic anemia. Bone marrow (BM) examination revealed erythroid dysplasia and cytoplasmic blasts, and hence the patient was diagnosed with myelodysplastic syndrome with ring sideroblasts and with single lineage dysplasia (MDS-RS-SLD). Erythrocyte transfusion was performed as a supportive therapy, and there was a gradual increase in the number of blood cells. Therefore, BM re-examination was performed and it was confirmed that the number of megakaryocytes increased, so the patient's condition was determined as myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T). Incidentally, gene mutation analysis showed CALR gene mutation. Thereafter, administration of hydroxycarbamide and anagrelide did not show adverse events and complications, and a good blood count control was obtained. Furthermore, it was also confirmed that an SF3B1 gene mutation is highly positive in MDS-RS. There was no report on CALR-mutant MDS/MPN in Japan, and it is a rare disease overseas.
MeSH term(s)	Aged, 80 and over ; Calreticulin/genetics ; Female ; Hematologic Neoplasms/genetics ; Humans ; Japan ; Mutation ; Phosphoproteins/genetics ; RNA Splicing Factors/genetics ; Thrombocytosis/genetics
Chemical Substances	CALR protein, human ; Calreticulin ; Phosphoproteins ; RNA Splicing Factors ; SF3B1 protein, human
Language	Japanese
Publishing date	2019-09-04
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
DOI	10.11406/rinketsu.60.915
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Whole brain radiation therapy for primary central nervous system marginal zone lymphoma: a case report.

Sato, Genki Edward / Ikeda, Itaru / Sakoda, Marie / Matsugi, Kiyotomo / Utsumi, Takahiko / Iwasa, Yoko / Yamauchi, Chikako

International cancer conference journal

2020 Volume 10, Issue 1, Page(s) 31–34

Abstract: A standard radiation therapy protocol for primary central nervous system marginal zone lymphoma (CNS-MZL) has not been established. The International Lymphoma Radiation Oncology Group suggested a radiation therapy dose of 30-36 Gy for lesions of well- ... ...

Abstract	A standard radiation therapy protocol for primary central nervous system marginal zone lymphoma (CNS-MZL) has not been established. The International Lymphoma Radiation Oncology Group suggested a radiation therapy dose of 30-36 Gy for lesions of well-defined CNS-MZL. We report a case of relatively low-dose whole brain radiation therapy (WBRT) for ill-defined CNS-MZL. A 56-year-old man who presented with sudden left-sided convulsions and impaired consciousness was diagnosed with CNS-MZL. The tumor had an ill-defined lesion, without cerebrospinal fluid involvement. WBRT, consisting of 25.2 Gy in 14 fractions, was administered owing to the difficulty in target delineation for focal radiation therapy. No chemotherapy was administered during the treatment course. After the 36-month follow-up period, the patient maintained complete remission without neurological disorders. This report describes the usefulness of relatively low-dose WBRT for ill-defined CNS-MZL.
Language	English
Publishing date	2020-09-08
Publishing country	Singapore
Document type	Case Reports
ISSN	2192-3183
ISSN (online)	2192-3183
DOI	10.1007/s13691-020-00443-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: [Annuloaortic ectasia associated with antithrombin III deficiency; report of a case].

Fujiwara, Yasue / Yamada, Tomoyuki / Katsuyama, Kazuhiko / Utsumi, Takahiko

Kyobu geka. The Japanese journal of thoracic surgery

2013 Volume 66, Issue 7, Page(s) 589–592

Abstract: A 33-year-old male with hereditary deficiency of antithrombin III (AT III) was diagnosed with annuloaortic ectasia and scheduled for the aortic root replacement. As perioperative anticoagulation, AT III was administered to have its activity≥70% in ... ...

Abstract	A 33-year-old male with hereditary deficiency of antithrombin III (AT III) was diagnosed with annuloaortic ectasia and scheduled for the aortic root replacement. As perioperative anticoagulation, AT III was administered to have its activity≥70% in addition to heparin. During the operation with cardiopulmonary bypass, 3,000 IU of AT III concentrate was infused, and there was no hemorrhagic complication. After the operation low-molecular-weight heparin was used instead of unfractionated heparin to avoid bleeding. However, renal infarction occurred on postoperative day 11. Heparin was continuously given in combination with 1,500 IU/day of AT III concentrate until oral warfarin reached within therapeutic range. The patient recovered without further sequelae. Cardiac surgery might be safely performed in patients with AT III deficiency by replenishing AT III concentrate to keep its activity higher than 80%.
MeSH term(s)	Adult ; Antithrombin III/administration & dosage ; Antithrombin III Deficiency/complications ; Aortic Aneurysm, Thoracic/complications ; Aortic Aneurysm, Thoracic/surgery ; Heparin/administration & dosage ; Humans ; Male
Chemical Substances	Antithrombin III (9000-94-6) ; Heparin (9005-49-6)
Language	Japanese
Publishing date	2013-07
Publishing country	Japan
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	603899-2
ISSN	0021-5252
ISSN	0021-5252
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 11: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Maruyama, Dai / Iida, Shinsuke / Machida, Ryunosuke / Kusumoto, Shigeru / Fukuhara, Noriko / Yamauchi, Nobuhiko / Miyazaki, Kana / Yoshimitsu, Makoto / Kuroda, Junya / Tsukamoto, Norifumi / Tsujimura, Hideki / Usuki, Kensuke / Yamauchi, Takahiro / Utsumi, Takahiko / Mizuno, Ishikazu / Takamatsu, Yasushi / Nagata, Yasuyuki / Ota, Shuichi / Ohtsuka, Eiichi /

Hanamura, Ichiro / Suzuki, Yasuhiro / Yoshida, Shinichiro / Yamasaki, Satoshi / Suehiro, Youko / Kamiyama, Yutaro / Fukuhara, Suguru / Tsukasaki, Kunihiro / Nagai, Hirokazu

Cancer science

2022 Volume 113, Issue 9, Page(s) 3267–3270

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Clinical Trials, Phase II as Topic ; Humans ; Melphalan/therapeutic use ; Multiple Myeloma/drug therapy ; Prednisolone/therapeutic use ; Randomized Controlled Trials as Topic
Chemical Substances	Bortezomib (69G8BD63PP) ; Prednisolone (9PHQ9Y1OLM) ; Melphalan (Q41OR9510P)
Language	English
Publishing date	2022-07-31
Publishing country	England
Document type	Letter
ZDB-ID	2115647-5
ISSN	1349-7006 ; 1349-7006
ISSN (online)	1349-7006
ISSN	1349-7006
DOI	10.1111/cas.15484
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.

Ogura, Michinori / Yamamoto, Kazuhito / Morishima, Yasuo / Wakabayashi, Masashi / Tobinai, Kensei / Ando, Kiyoshi / Uike, Naokuni / Kurosawa, Mitsutoshi / Gomyo, Hiroshi / Taniwaki, Masafumi / Nosaka, Kisato / Tsukamoto, Norifumi / Shimoyama, Tatsu / Fukuhara, Noriko / Yakushijin, Yoshihiro / Ohnishi, Kazunori / Miyazaki, Kana / Kameoka, Yoshihiro / Takayama, Nobuyuki /

Hanamura, Ichiro / Kobayashi, Hirofumi / Usuki, Kensuke / Kobayashi, Naoki / Ohyashiki, Kazuma / Utsumi, Takahiko / Kumagai, Kyoya / Maruyama, Dai / Ohmachi, Ken / Matsuno, Yoshihiro / Nakamura, Shigeo / Hotta, Tomomitsu / Tsukasaki, Kunihiro / Nagai, Hirokazu

Cancer science

2023 Volume 114, Issue 8, Page(s) 3461–3465

Abstract: Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed. ...

Abstract	Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed.
MeSH term(s)	Adult ; Humans ; Lymphoma, Mantle-Cell/diagnostic imaging ; Lymphoma, Mantle-Cell/drug therapy ; Follow-Up Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Recurrence, Local ; Rituximab/therapeutic use ; Vincristine/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Prednisone/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Cyclophosphamide (8N3DW7272P) ; Doxorubicin (80168379AG) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2023-05-26
Publishing country	England
Document type	Letter
ZDB-ID	2115647-5
ISSN	1349-7006 ; 1349-7006
ISSN (online)	1349-7006
ISSN	1349-7006
DOI	10.1111/cas.15849
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.

Miyazaki, Kana / Suzuki, Ritsuro / Oguchi, Masahiko / Taguchi, Senzo / Amaki, Jun / Maeda, Takeshi / Kubota, Nobuko / Maruyama, Dai / Terui, Yasuhito / Sekiguchi, Nodoka / Takizawa, Jun / Tsukamoto, Hiroyuki / Murayama, Tohru / Ando, Toshihiko / Matsuoka, Hiroshi / Hasegawa, Masatoshi / Wada, Hideho / Sakai, Rika / Kameoka, Yoshihiro /

Tsukamoto, Norifumi / Choi, Ilseung / Masaki, Yasufumi / Shimada, Kazuyuki / Fukuhara, Noriko / Utsumi, Takahiko / Uoshima, Nobuhiko / Kagami, Yoshitoyo / Asano, Naoko / Ejima, Yasuo / Katayama, Naoyuki / Yamaguchi, Motoko

Hematological oncology

2022 Volume 40, Issue 4, Page(s) 667–677

Abstract: To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 ... ...

Abstract	To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 and 2013 in a nationwide retrospective study in Japan were updated and analyzed. At a median follow-up of 8.4 years, the 5-year overall survival (OS) and progression-free survival (PFS) were 71% and 64%, respectively, in 140 localized ENKTL patients who received radiotherapy-dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) in clinical practice. Nine (6.4%) patients experienced second malignancies. In 155 localized ENKTL patients treated with RT-DeVIC, 10 (6.5%) experienced CNS relapse (median, 12.8 months after diagnosis). In five of them, the events were confined to the CNS. Nine of the 10 patients who experienced CNS relapse died within 1 year after CNS relapse. Multivariate analysis identified gingival (hazard ratio [HR], 54.35; 95% confidence interval [CI], 8.60-343.35) and paranasal involvement (HR, 7.42; 95% CI, 1.78-30.89) as independent risk factors for CNS relapse. In 80 advanced ENKTL patients, 18 received steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment. Patients who received SMILE as their first-line treatment tended to have better OS than those who did not (p = 0.071). Six (7.5%) advanced ENKTL patients experienced isolated CNS relapse (median, 2.6 months after diagnosis) and died within 4 months of relapse. No second malignancies were documented in advanced ENKTL patients. In the entire cohort, the median OS after first relapse or progression was 4.6 months. 12 patients who survived 5 years after PFS events were disease-free at the last follow-up. Of those, 11 (92%) underwent hematopoietic stem cell transplantation. Our 8-year follow-up revealed the long-term efficacy and safety of RT-DeVIC and SMILE. The risk of CNS relapse is an important consideration in advanced ENKTL.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Asparaginase ; Carboplatin ; Central Nervous System/pathology ; Dexamethasone ; Etoposide ; Humans ; Ifosfamide ; Killer Cells, Natural/pathology ; Lymphoma, Extranodal NK-T-Cell/diagnosis ; Lymphoma, Extranodal NK-T-Cell/drug therapy ; Methotrexate ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies
Chemical Substances	Etoposide (6PLQ3CP4P3) ; Dexamethasone (7S5I7G3JQL) ; Carboplatin (BG3F62OND5) ; Asparaginase (EC 3.5.1.1) ; Ifosfamide (UM20QQM95Y) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2022-03-02
Publishing country	England
Document type	Journal Article
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.2977
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).

Maruyama, Dai / Iida, Shinsuke / Ogawa, Gakuto / Fukuhara, Noriko / Seo, Sachiko / Miyazaki, Kana / Yoshimitsu, Makoto / Kuroda, Junya / Tsukamoto, Norifumi / Tsujimura, Hideki / Hangaishi, Akira / Yamauchi, Takahiro / Utsumi, Takahiko / Mizuno, Ishikazu / Takamatsu, Yasushi / Nagata, Yasuyuki / Minauchi, Koichiro / Ohtsuka, Eiichi / Hanamura, Ichiro /

Yoshida, Shinichiro / Yamasaki, Satoshi / Suehiro, Youko / Kamiyama, Yutaro / Tsukasaki, Kunihiro / Nagai, Hirokazu

British journal of haematology

2020 Volume 192, Issue 3, Page(s) 531–541

Abstract: We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly ... ...

Abstract	We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45·8 and 35·1 mg/m
MeSH term(s)	Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Bortezomib/therapeutic use ; Female ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Multiple Myeloma/drug therapy ; Prednisolone/administration & dosage ; Prednisolone/adverse effects ; Prednisolone/therapeutic use ; Survival Analysis ; Treatment Outcome
Chemical Substances	Bortezomib (69G8BD63PP) ; Prednisolone (9PHQ9Y1OLM) ; Melphalan (Q41OR9510P)
Language	English
Publishing date	2020-06-24
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.16878
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: [Fungemia caused by Scedosporium prolificans in myelodysplastic syndrome].

Nishio, Hisaaki / Utsumi, Takahiko / Nakamura, Yukiko / Suzuki, Takayo / Kamei, Katsuhiko / Saitoh, Takashi

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases

2010 Volume 86, Issue 1, Page(s) 22–26

Abstract: We report a case of fungemia caused by Scedosporium prolificans, an emerging pathogen. An 83-year-old man with myelodysplastic syndrome (MDS) and agranulocytosis was admitted for pneumonia in January 2009. He was treated with meropenem, minocycline, and ... ...

Abstract	We report a case of fungemia caused by Scedosporium prolificans, an emerging pathogen. An 83-year-old man with myelodysplastic syndrome (MDS) and agranulocytosis was admitted for pneumonia in January 2009. He was treated with meropenem, minocycline, and gamma-globulin for pneumonia and G-CSF and platelet transfusion for MDS. Although he recovered from pneumonia as neutrophil count increased, intermittent fever continued. On hospital day 17, blood culture yielded fungal colonies indicating S. prolificans. Voriconazole was started immediately, but the man's general condition deteriorated with cerebral infarction and he died of cerebral hemorrhage on hospital day 65. Attention must therefore be paid to the increasing scedosporiosis incidence in Japan.
MeSH term(s)	Aged, 80 and over ; Fungemia/complications ; Humans ; Male ; Myelodysplastic Syndromes/complications ; Opportunistic Infections ; Scedosporium
Language	Japanese
Publishing date	2010-07-25
Publishing country	Japan
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	605664-7
ISSN	0387-5911
ISSN	0387-5911
DOI	10.11150/kansenshogakuzasshi.86.22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 507: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

Ohmachi, Ken / Kinoshita, Tomohiro / Tobinai, Kensei / Ogawa, Gakuto / Mizutani, Tomonori / Yamauchi, Nobuhiko / Fukuhara, Noriko / Uchida, Toshiki / Yamamoto, Kazuhito / Miyazaki, Kana / Tsukamoto, Norifumi / Iida, Shinsuke / Utsumi, Takahiko / Yoshida, Isao / Imaizumi, Yoshitaka / Tokunaga, Takashi / Yoshida, Shinichiro / Masaki, Yasufumi / Murayama, Tohru /

Yakushijin, Yoshihiro / Suehiro, Youko / Nosaka, Kisato / Dobashi, Nobuaki / Kuroda, Junya / Takamatsu, Yasushi / Maruyama, Dai / Ando, Kiyoshi / Ishizawa, Kenichi / Ogura, Michinori / Yoshino, Tadashi / Hotta, Tomomitsu / Tsukasaki, Kunihiro / Nagai, Hirokazu

Blood advances

2021 Volume 5, Issue 4, Page(s) 984–993

Abstract: Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP ...

Abstract	Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (RW-CHOP) in patients with untreated DLBCL, we conducted a phase 2/3 study (JCOG0601, jRCTs031180139). Patients were randomly assigned to R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2]) or RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2]) groups. The primary end point of the phase 2 component was percent complete response (%CR) of the RW-CHOP arm, whereas that of the phase 3 component was progression-free survival (PFS). Between December 2007 and December 2014, 421 untreated patients were randomly assigned to R-CHOP (213 patients) or RW-CHOP (208 patients). The %CR in the RW-CHOP arm was 85.3% and therefore met the prespecified decision criteria for the phase 2 component. With a median follow-up of 63.4 months, the 3-year PFS and overall survival were 79.2% and 88.7% in the R-CHOP arm and 80.3% and 90.4% in the RW-CHOP arm, respectively. There was no significant difference in PFS (hazard ratio, 0.95; 90.6% confidence interval, 0.68-1.31). Although the safety profile and efficacy of RW-CHOP was comparable with R-CHOP and its tolerability was acceptable, weekly rituximab in combination with CHOP during the early treatment period did not improve PFS in untreated patients with DLBCL. This trial was registered at jrct.niph.go.jp as #jRCTs031180139.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Prednisone/therapeutic use ; Rituximab/therapeutic use ; Vincristine/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2021-02-16
Publishing country	United States
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2020002567
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito